Yahoo Finance

Rein Therapeutics Enters into Agreements for up to $21 Million in Flexible Financing

AUSTIN, Texas, July 30, 2025 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant ...
Yahoo Finance

Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and ...
Seeking Alpha

Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis

AUSTIN, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics (RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical ...
Nasdaq

Rein Therapeutics Rebrands And Focuses On Pulmonary And Fibrosis Therapies

(RTTNews) - Rein Therapeutics (RNTX), formerly Aileron Therapeutics(ALRN), announced on Friday its rebranding to reflect its focus on developing therapies for orphan pulmonary and fibrosis indications ...